Want to see TSE:MPH full AI Analyst Report?
MPH Stock Chart & Stats
C$1.25
C$0.01(1.22%)
At close: 4:00 PM EST
C$1.25
C$0.01(1.22%)
Day’s Range― - ―
52-Week RangeC$0.85 - C$1.43
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.72K
Market Cap
C$11.17M
Enterprise ValueC$9.70M
Total Cash (Recent Filing)C$1.54M
Total Debt (Recent Filing)C$803.00K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding10,436,313
10 Day Avg. Volume717
30 Day Avg. Volume1,717
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Cardiovascular FocusA focused therapeutic niche in cardiovascular care gives Medicure durable domain expertise, sales channel relationships, and regulatory familiarity. That specialty positioning supports repeatable product commercialization and targeted R&D, reducing blockbuster dependency and enabling stable market positioning over months.
Commercialization-driven Revenue ModelRevenue primarily from marketing and selling prescription products creates recurring, contract-linked cash streams and predictable channel flows. Commercialization and licensing structures (sales, distributor contracts, milestone/royalty potential) lower binary R&D risk and provide enduring cash generation levers.
Low Financial LeverageVery low debt materially reduces refinancing and solvency risk, preserving flexibility to fund operations, R&D or commercialization through existing capital or modest financing. This conservatism supports survival through temporary cash burn and underpins strategic optionality over months.
Bears Say
Sharp Gross Margin CompressionA rapid decline in gross margins signals structural pressure from pricing, higher COGS, reimbursement or unfavorable product mix. Sustained margin erosion reduces ability to fund commercialization and R&D internally and makes the business more sensitive to volume swings and competitive pricing over the medium term.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates operational cash burn rather than generation. Over 2–6 months this increases reliance on external funding, risks dilution or higher-cost capital, and constrains investments in sales, marketing, or trials that are needed to restore profitable growth.
Ongoing Losses And Equity ErosionMaterial net losses and declining shareholder equity indicate the company is burning book value. Continued negative margins and shrinking equity reduce resilience to setbacks, impair credit access and increase the probability of dilutive financing if profitable operations are not restored in the near term.
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.85 and its highest was C$1.43 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$11.17M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Aug 26, 2026 which is in 35 days.
How were Medicure Inc’s earnings last quarter?
Currently, no data Available
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―